Duane C. Bloedow

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial

Charles J. Fisher, Gus J. Slotman, Steven M. Opal et al. · Critical Care Medicine · 1994 · 490 citations

Medicine, Pharmacokinetics, Pharmacology +14

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

E Fischer, Michael A. Marano, Kimberly J. Van Zee et al. · Journal of Clinical Investigation · 1992 · 335 citations · Full text

Veterinary Medicine, Immunology, Microbiology +14

Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Robert B. Kimble, J L Vannice, Duane C. Bloedow et al. · Journal of Clinical Investigation · 1994 · 233 citations · Full text

Medicine, Endocrinology, Bone Metabolism +16

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans

Eric V. Granowitz, Reuven Porat, James W. Mier et al. · Cytokine · 1992 · 222 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)

Manuel Hidalgo, Duane C. Bloedow · Seminars in Oncology · 2003 · 99 citations

Pharmacy, Pharmacokinetics, Pharmacology +12